Hospital-acquired infection (HAI), also known as a nosocomial infection, is an infection caused by bacteria, fungi, or viruses while receiving treatment in a healthcare facility. Surgical site infection (SSI), Urinary tract infection (UTI), pneumonia, and bloodstream infection are the most prevalent HAIs (BSI). Chronic diseases such as cancer, heart disease, diabetes, and arthritis have become a serious public health concern in recent decades, with an increasing prevalence worldwide. Hospital admissions have increased as a result of the high prevalence of these chronic diseases.
Treatment for hospital-acquired infections varies depending on the type of infection and the portion of the body afflicted. In the coming years, the high prevalence of these HAIs is projected to boost demand for treatments and fuel market expansion. Because of the rising number of UTI cases and increasing awareness among people regarding the disease condition, urinary tract infections (UTIs) are expected to increase at the quickest rate in the near future.
Major Influencing Factors for Hospital Acquired Infections Therapeutic Market
Increased hospitalizations as a result of the increased incidence of chronic diseases are expected to lead to an increase in HAI cases, boosting the market for hospital-acquired infections therapeutic. The market is likely to develop as people become more aware of the numerous risk factors related to HAIs in ICUs and other emergency care settings. Furthermore, rising healthcare awareness, the availability of advanced medical facilities, and government initiatives for healthcare management are all likely to contribute to the target market’s revenue growth. The government is launching measures to create patient safety networks, and quality-focused organizations are collaborating to improve infection control and minimize the number of patients who develop these illnesses.
Key Dynamics in Different Regional Markets
The North American region is expected to have a large market share, owing to the rising incidence of multidrug-resistant infections and the existence of prominent market players focused on developing new therapeutic alternatives. Because of the presence of emerging and undeveloped healthcare centers with little understanding of hospital infection control systems and a rising incidence of hospital-acquired illnesses, the Asia Pacific hospital-acquired infections therapeutic treatments market is expected to rise at a significant rate. Furthermore, the company’s desire to expand into previously untapped markets in the Asia Pacific area is expected to stimulate regional growth.
Players Holding Dominant Position in the Market
On the back of a big patient pool, economic expansion is creating opportunities for manufacturers. Major businesses are concentrating their efforts on diverse R&D initiatives to combat the rising rate of hospital-acquired illnesses. In the medical field, innovations aimed at preventing cross-contamination and improving patient safety are gaining popularity. Players in the hospital-acquired infections therapeutic market are putting a lot of effort into R&D to develop new HAI medications and get them approved in major markets.
The key players present in the hospital-acquired infections therapeutic market include AbbVie Inc., Bayer AG, Abbott Laboratories, Pfizer Inc., Daiichi Sankyo Company, Merck, Allergan Plc., GlaxoSmithKline Plc., and F. Hoffmann-La Roche Ltd, Limited. These market leaders are forming several strategies such as collaborations, product development, and product launches to gain a competitive advantage in the market.
Deep-dive Insights on Hospital Acquired Infections Therapeutic Market by Polaris Market Research: https://www.polarismarketresearch.com/industry-analysis/hospital-acquired-infections-therapeutic-market/request-for-sample